Cassava Sciences Beheer

Beheer criteriumcontroles 2/4

De CEO Cassava Sciences is Rick Barry, benoemd in Sep2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.98% van de aandelen van het bedrijf, ter waarde MX$ 41.68M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 6.8 jaar.

Belangrijke informatie

Rick Barry

Algemeen directeur

US$546.2k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

CEO

Rick Barry (65 yo)

less than a year

Tenure

US$546,155

Compensatie

Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Barry	CEO, President & Director	less than a year	US$546.16k	0.98% MX$ 41.7m
Eric Schoen	Chief Financial Officer	6.1yrs	US$2.99m	0.048% MX$ 2.1m
R. Cook	Senior VP	2.1yrs	US$1.27m	0% MX$ 0
James Kupiec	Chief Medical Officer	3.8yrs	US$2.97m	0.0083% MX$ 354.8k
George Thornton	Senior Vice President of Technology	no data	geen gegevens	geen gegevens
Michael Zamloot	Senior Vice President of Technical Operations	no data	geen gegevens	geen gegevens
Michael Marsman	Senior Vice President of Regulatory Affairs	2yrs	geen gegevens	geen gegevens
Lindsay Burns	Senior Vice President of Neuroscience	4.6yrs	geen gegevens	geen gegevens
Freda Nassif	Chief Commercial Officer	no data	geen gegevens	geen gegevens
Jaren Landen	Chief Clinical Development Officer	no data	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SAVA * wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Barry	CEO, President & Director	3.4yrs	US$546.16k	0.98% MX$ 41.7m
Patrick Scannon	Independent Director	16.9yrs	US$438.42k	0.0025% MX$ 106.3k
Michael O'Donnell	Independent Director	26.4yrs	US$438.42k	0.017% MX$ 731.9k
Grant Schoenhard	Member of Scientific Advisory Board	10.1yrs	US$558.31k	geen gegevens
Robert Gussin	Independent Director	21.7yrs	US$546.16k	0.026% MX$ 1.1m
Claude Nicaise	Independent Chairman	less than a year	US$474.50k	0% MX$ 0
Robert Anderson	Independent Director	less than a year	US$474.50k	0% MX$ 0
Pierre Gravier	Independent Director	less than a year	US$474.50k	0% MX$ 0

6.8yrs

Gemiddelde duur

68.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SAVA * wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Cassava Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Board Appointments

Recent updates

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

Forecast breakeven date moved forward to 2025

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Forecast breakeven date pushed back to 2024

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Independent Director recently bought Mex$42m worth of stock

Forecast to breakeven in 2023

Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Executive Changes

Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel

Cassava Sciences Announces Initiation of an Open-Label Extension Study

Chief Clinical Development Officer recently bought Mex$1.2m worth of stock

Lead Independent Director recently bought Mex$41m worth of stock

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Cassava Sciences Announces Top-Line Results of 12-Month Interim Analysis from Open-Label Study Evaluating Simufilam in Alzheimer’s Disease

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Cassava Sciences, Inc

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Cassava Sciences, Inc.(NasdaqCM:SAVA) dropped from Russell Microcap Growth Index

Cassava Sciences, Inc. Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’S Disease

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd